Physician profile
Malcolm P Pyles
NPI 1023570041
$8,056.03
in general payments reported to CMS, 2019-2025
20 companies · $4,523 in 2025
The $4,523 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $23.73 · 2021: $41.48 · 2022: $13.42 · 2023: $648 · 2024: $2,489 · 2025: $4,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,466 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,465.91 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,227.60 | 2023-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,009.41 | 2020-2025 | |
| Incyte Corporation | $835.90 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $637.79 | 2024-2025 | Bimzelx |
| Organon LLC | $627.20 | 2025 | Vtama |
| Pfizer INC. | $521.28 | 2024-2025 | |
| Galderma Laboratories, L.P. | $495.90 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $482.42 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $375.34 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $340.54 | 2023-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $300.00 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $266.64 | 2023-2025 | Adbry |
| Amgen INC. | $261.32 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $221.75 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $167.09 | 2023-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Genentech USA, INC. | $79.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $77.59 | 2024-2025 | Sotyktu |
| Allergan, INC. | $20.29 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Pyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.